ACM
CATX icon

Altium Capital Management’s Perspective Therapeutics CATX Stock Holding History

Altium Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-92,224
Closed -$294K – 35
2024
Q4 		$294K Sell
92,224
-197,776
-68% -$1.61M 0.08% 62
2024
Q3 		$3.87M Buy
290,000
+98,550
+51% +$1.31M 1.14% 33
2024
Q2 		$1.91M Buy
191,450
+137,884
+257% +$1.99M 0.78% 29
2024
Q1 		$637K Buy
+53,566
New +$457K 0.25% 44

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Altium Capital Management's CATX Position: Q1 2025 in Review

Altium Capital Management sold out of Perspective Therapeutics (CATX) in Q1 2025, closing a stake of 92,224 shares — an estimated $294K sold.

Altium Capital Management first reported a position in CATX in Q1 2024 and held it in 4 quarters. The position peaked at $3.87M in Q3 2024. 112 funds tracked by Wall St. Rank hold CATX as of Q1 2025.

  • Altium Capital Management reported no remaining Perspective Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Altium Capital Management sold 92,224 Perspective Therapeutics shares in Q1 2025, an estimated $294K.
  • Altium Capital Management first reported a position in Perspective Therapeutics in Q1 2024 and held it in 4 quarters.
  • Altium Capital Management's Perspective Therapeutics position peaked at $3.87M in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.